Hydrochlorothiazide to help polycystic kidney disease and quality of life
Treatments studied
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 3 study tests whether hydrochlorothiazide can help people with autosomal dominant polycystic kidney disease (ADPKD) and improve quality of life. It also looks at whether it affects kidney health while you stay on your current ADPKD-related treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with ADPKD (autosomal dominant polycystic kidney disease).
- You’re at least 18 years old.
- Your kidney function is not too low (eGFR is above 25).
- You’ve been on the highest tolerated dose of a V2 receptor blocker (V2RA) for at least 3 months.
- Your blood pressure is not too low (no dizziness on standing) and not too high (not above 160/100).
- You can’t have certain issues: hydrochlorothiazide intolerance, current diuretic use, low potassium, frequent gout, or a past skin cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at people with autosomal dominant polycystic kidney disease to learn more about the condition. It is an observational study, meaning no new treatments are tested—just gathering information from your medical history and tests.
This trial tests a new study drug called AZD1613 for adults with a certain type of kidney disease (ADPKD). Researchers want to see if it is safe, how the body handles it, and what the right dose might be.
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
This Phase 3 study tests whether taking metformin can slow the decline of kidney function in adults with autosomal dominant polycystic kidney disease (ADPKD). You may be eligible if you have ADPKD and signs that your kidneys are starting to decline faster than expected.
This Phase 2 study tests whether atorvastatin plus an “alkalizing” treatment (sodium bicarbonate) can slow or improve disease effects in people with autosomal dominant polycystic kidney disease (ADPKD). It specifically targets metabolic acidosis (when the body becomes “too acidic”), which may worsen kidney health.
This trial tests if the cholesterol-lowering drug bempedoic acid can slow kidney function loss in people with autosomal dominant polycystic kidney disease (ADPKD). It may offer a new option to protect your kidneys.
Hear when a new ADPKD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.